Unmet Needs in Relapsed or Refractory DLBCL
Efficacy and Safety Results
Dosage, Administration, and Handling of ZYNLONTA
Questions & Answers
ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please click here for the full Prescribing Information, including Patient Information.
Please see full Prescribing Information, including Patient Information.